SG10201606618PA - Oral formulations and lipophilic salts of methylnaltrexone - Google Patents

Oral formulations and lipophilic salts of methylnaltrexone

Info

Publication number: SG10201606618PA
Authority: SG; Singapore
Prior art keywords: methylnaltrexone; oral formulations; lipophilic salts; lipophilic; salts
Prior art date: 2010-03-11

Application number

SG10201606618PA

Inventor

Syed M Shah

Christopher Richard Diorio

Eric C Ehrnsperger

Xu Meng

Shareffi Kadum A Al

Jonathan Marc Cohen

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-11

Filing date

2011-03-10

Publication date

2016-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201606618P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-10 Application filed by Wyeth Llc filed Critical Wyeth Llc

2016-09-29 Publication of SG10201606618PA publication Critical patent/SG10201606618PA/en

Links

JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical class C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 title 1
238000009472 formulation Methods 0.000 title 1
229960002921 methylnaltrexone Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG10201606618PA 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone SG10201606618PA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31301810P	2010-03-11	2010-03-11

Publications (1)

Publication Number	Publication Date
SG10201606618PA true SG10201606618PA (en)	2016-09-29

Family

ID=44148539

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201501821RA SG10201501821RA (en)	2010-03-11	2011-03-10	Oral formulations and lipophilic salts of methylnaltrexone
SG2012057261A SG183133A1 (en)	2010-03-11	2011-03-10	Oral formulations and lipophilic salts of methylnaltrexone
SG10201606618PA SG10201606618PA (en)	2010-03-11	2011-03-10	Oral formulations and lipophilic salts of methylnaltrexone

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SG10201501821RA SG10201501821RA (en)	2010-03-11	2011-03-10	Oral formulations and lipophilic salts of methylnaltrexone
SG2012057261A SG183133A1 (en)	2010-03-11	2011-03-10	Oral formulations and lipophilic salts of methylnaltrexone

Country Status (32)

Country	Link
US (8)	US8524276B2 (en)
EP (2)	EP2371357B1 (en)
JP (4)	JP6143409B2 (en)
KR (2)	KR101913102B1 (en)
CN (2)	CN102918039B (en)
AR (1)	AR080491A1 (en)
AU (1)	AU2011224275B2 (en)
BR (1)	BR112012022873B1 (en)
CA (1)	CA2789798C (en)
CL (1)	CL2012002192A1 (en)
CO (1)	CO6630134A2 (en)
CR (1)	CR20120476A (en)
EA (1)	EA029096B1 (en)
EC (1)	ECSP12012208A (en)
ES (1)	ES2623926T3 (en)
GE (1)	GEP201606550B (en)
GT (1)	GT201200247A (en)
HU (1)	HUE033133T2 (en)
IL (1)	IL221452A (en)
MA (1)	MA34146B1 (en)
MX (2)	MX349145B (en)
MY (1)	MY160727A (en)
NZ (3)	NZ703564A (en)
PE (1)	PE20130063A1 (en)
PH (1)	PH12012501622A1 (en)
PL (2)	PL2371357T3 (en)
SG (3)	SG10201501821RA (en)
TN (1)	TN2012000392A1 (en)
TW (2)	TWI589293B (en)
UA (2)	UA123856C2 (en)
WO (1)	WO2011112816A1 (en)
ZA (1)	ZA201808498B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20150037T4 (en)	2003-04-08	2022-09-02	Progenics Pharmaceuticals, Inc.	PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
TWI489984B (en)	2006-08-04	2015-07-01	Wyeth Corp	Formulations for parenteral delivery of compounds and uses thereof
CA2865389A1 (en)	2007-03-29	2008-10-09	Progenics Pharmaceuticals, Inc.	Crystal forms and uses thereof
US9061076B2 (en)	2007-05-25	2015-06-23	North Carolina State University	Viral nanoparticle cell-targeted delivery platform
SG10201501821RA (en)	2010-03-11	2015-05-28	Wyeth Llc	Oral formulations and lipophilic salts of methylnaltrexone
US8939943B2 (en)	2011-01-26	2015-01-27	Kaleo, Inc.	Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en)	2011-02-28	2014-01-14	Intelliject, Inc.	Medicament delivery device for administration of opioid antagonists including formulations for naloxone
AU2012359013A1 (en) *	2011-12-19	2014-06-26	Salix Pharmaceuticals, Ltd.	Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) *	2014-06-10	2015-12-17	Salix Pharmaceuticals, Inc.	Methods of administering methylnaltrexone
US11135155B2 (en)	2014-07-08	2021-10-05	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
JP2017519803A (en) *	2014-07-08	2017-07-20	インシス・ファーマ・インコーポレーテッド	Sublingual naloxone spray
US10722510B2 (en) *	2014-07-08	2020-07-28	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
US10617686B2 (en) *	2014-07-08	2020-04-14	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
US10441538B2 (en) *	2014-07-08	2019-10-15	Hikma Pharmaceuticals Usa Inc.	Liquid naloxone spray
CA3002137A1 (en)	2014-10-17	2016-04-21	Salix Pharmaceuticals, Inc.	Use of methylnaltrexone to attenuate tumor progression
WO2020128583A1 (en) *	2018-12-19	2020-06-25	Friulchem S.P.A.	Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CN113747882A (en) *	2019-05-07	2021-12-03	博士医疗爱尔兰有限公司	Liquid oral dosage formulations of methylnaltrexone
WO2020245214A1 (en)	2019-06-03	2020-12-10	Bausch Health Ireland Limited	Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3177250A1 (en)	2020-05-02	2021-11-11	Bausch Health Ireland Limited	Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) *	2021-08-28	2023-03-09	Redasani Vijayendrakumar Virendrakumar Ji	Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4176186A (en)	1978-07-28	1979-11-27	Boehringer Ingelheim Gmbh	Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en)	1986-03-07	1989-08-29	The University Of Chicago	Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en)	1986-03-07	1988-01-12	University Of Chicago	Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en)	1986-03-14	1992-03-10	Edward David Weil	Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en)	1989-02-17	1992-04-07	Arch Development Corporation	Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en)	1990-06-21	1998-07-14	Huland; Edith	Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en)	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en)	1994-10-07	1999-02-02	The Dupont Merck Pharmaceutical Company	Stabilized naloxone formulations
DE19651551C2 (en)	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioid antagonist-containing galenic formulation
ATE186643T1 (en)	1997-02-14	1999-12-15	Goedecke Ag	STABILIZATION OF NALOXONE HYDROCHLORIDE
US6274591B1 (en)	1997-11-03	2001-08-14	Joseph F. Foss	Use of methylnaltrexone and related compounds
US20030158220A1 (en)	1997-11-03	2003-08-21	Foss Joseph F.	Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en)	1997-11-03	1999-10-26	Arch Development Corporation	Use of methylnaltrexone and related compounds
EP0913152B1 (en)	1997-11-03	2001-12-19	Stada Arzneimittel Ag	Stabilised combination of drugs comprising naloxone and an opioid analgesic
US6559158B1 (en)	1997-11-03	2003-05-06	Ur Labs, Inc.	Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
GB0100115D0 (en)	2001-01-04	2001-02-14	Alchemia Pty Ltd	Delivery systems
CA2446550C (en) *	2001-05-11	2012-03-06	Endo Pharmaceuticals, Inc.	Abuse-resistant controlled-release opioid dosage form
DE60234183D1 (en)	2001-06-05	2009-12-10	Univ Chicago	USE OF METHYL NALTREXONE FOR THE TREATMENT OF IMMUNOSUPPRESSION
EP1436012B1 (en)	2001-10-18	2017-12-20	Nektar Therapeutics	Polymer conjugates of opioid antagonists
EP1451174B1 (en)	2001-11-29	2010-08-18	Schering Corporation	Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
WO2003077867A2 (en)	2002-03-14	2003-09-25	Euro-Celtique, S.A.	Naltrexone hydrochloride compositions
US20030191147A1 (en)	2002-04-09	2003-10-09	Barry Sherman	Opioid antagonist compositions and dosage forms
RU2373936C2 (en)	2003-04-08	2009-11-27	Проджиникс Фармасьютикалз, Инк.	Application of methyl naltrexone for treating irritable colon syndrome
HRP20150037T4 (en)	2003-04-08	2022-09-02	Progenics Pharmaceuticals, Inc.	PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
CA2521420A1 (en)	2003-04-08	2004-10-28	Progenics Pharmaceuticals, Inc.	Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
AU2004259208B2 (en) *	2003-07-15	2011-04-28	Evonik Corporation	Method for the preparation of controlled release formulations
US8946262B2 (en)	2003-12-04	2015-02-03	Adolor Corporation	Methods of preventing and treating gastrointestinal dysfunction
US20060009504A1 (en)	2003-12-19	2006-01-12	Schering Corporation	Pharmaceutical compositions
CA2551254A1 (en) *	2003-12-31	2005-07-21	Pfizer Products Inc.	Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CN1294728C (en)	2004-08-05	2007-01-10	华为技术有限公司	Method and system for providing QoS assurance in edge router
JP5238255B2 (en)	2004-09-30	2013-07-17	ベクトン・ディキンソン・アンド・カンパニー	Method for reducing or removing residues in glass containers and glass containers manufactured according to the same
US20060177380A1 (en) *	2004-11-24	2006-08-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (en) *	2005-05-25	2007-11-14	Progenics Pharm Inc	SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
TWI489984B (en)	2006-08-04	2015-07-01	Wyeth Corp	Formulations for parenteral delivery of compounds and uses thereof
WO2008021394A2 (en) *	2006-08-15	2008-02-21	Theraquest Biosciences, Llc	Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) *	2006-08-16	2012-01-10	Novartis Ag	Temporal photo-bleaching of colored lens care solutions and use thereof
AU2007322269A1 (en) *	2006-10-11	2008-05-29	Alpharma Pharmaceuticals, Llc	Pharmaceutical compositions
TW200843802A (en)	2007-02-09	2008-11-16	Drugtech Corp	Compositions for improving gastrointestinal nutrient and drug absorption
CA2865389A1 (en) *	2007-03-29	2008-10-09	Progenics Pharmaceuticals, Inc.	Crystal forms and uses thereof
SI2139890T1 (en) *	2007-03-29	2014-12-31	Wyeth Llc	Peripheral opioid receptor antagonists and uses thereof
JP5178064B2 (en) *	2007-06-27	2013-04-10	富士フイルム株式会社	Metal layer laminate having metal surface roughened layer and method for producing the same
KR20110004425A (en) *	2008-05-07	2011-01-13	넥타르 테라퓨틱스	Oral Administration of Peripheral Opioid Antagonists
CA2676881C (en)	2008-09-30	2017-04-25	Wyeth	Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (en) *	2009-08-04	2014-06-18	株式会社神戸製鋼所	Copper alloy with high strength and excellent bending workability
SG10201501821RA (en)	2010-03-11	2015-05-28	Wyeth Llc	Oral formulations and lipophilic salts of methylnaltrexone
TW201235609A (en) *	2010-07-13	2012-09-01	Koninkl Philips Electronics Nv	Low cost mounting of LEDs in TL-retrofit tubes

2011
- 2011-03-10 SG SG10201501821RA patent/SG10201501821RA/en unknown
- 2011-03-10 MY MYPI2012003442A patent/MY160727A/en unknown
- 2011-03-10 CA CA2789798A patent/CA2789798C/en active Active
- 2011-03-10 MX MX2012009125A patent/MX349145B/en active IP Right Grant
- 2011-03-10 WO PCT/US2011/027913 patent/WO2011112816A1/en not_active Ceased
- 2011-03-10 KR KR1020127026488A patent/KR101913102B1/en active Active
- 2011-03-10 TW TW100108143A patent/TWI589293B/en active
- 2011-03-10 CN CN201180013511.1A patent/CN102918039B/en active Active
- 2011-03-10 MA MA35290A patent/MA34146B1/en unknown
- 2011-03-10 AR ARP110100757A patent/AR080491A1/en unknown
- 2011-03-10 US US13/045,108 patent/US8524276B2/en active Active
- 2011-03-10 TW TW105105359A patent/TWI605814B/en active
- 2011-03-10 GE GEAP201112868A patent/GEP201606550B/en unknown
- 2011-03-10 NZ NZ703564A patent/NZ703564A/en unknown
- 2011-03-10 KR KR1020187030676A patent/KR101982482B1/en active Active
- 2011-03-10 PH PH1/2012/501622A patent/PH12012501622A1/en unknown
- 2011-03-10 BR BR112012022873-0A patent/BR112012022873B1/en active IP Right Grant
- 2011-03-10 EA EA201270741A patent/EA029096B1/en unknown
- 2011-03-10 PE PE2012001538A patent/PE20130063A1/en active IP Right Grant
- 2011-03-10 NZ NZ702826A patent/NZ702826A/en unknown
- 2011-03-10 SG SG2012057261A patent/SG183133A1/en unknown
- 2011-03-10 UA UAA201602306A patent/UA123856C2/en unknown
- 2011-03-10 SG SG10201606618PA patent/SG10201606618PA/en unknown
- 2011-03-10 CN CN201710321015.1A patent/CN107308125B/en active Active
- 2011-03-10 JP JP2011052316A patent/JP6143409B2/en active Active
- 2011-03-10 MX MX2015010803A patent/MX368805B/en unknown
- 2011-03-10 NZ NZ601595A patent/NZ601595A/en unknown
- 2011-03-10 AU AU2011224275A patent/AU2011224275B2/en active Active
- 2011-03-11 PL PL11157837T patent/PL2371357T3/en unknown
- 2011-03-11 ES ES11157837.3T patent/ES2623926T3/en active Active
- 2011-03-11 PL PL17153285T patent/PL3178472T3/en unknown
- 2011-03-11 EP EP11157837.3A patent/EP2371357B1/en active Active
- 2011-03-11 HU HUE11157837A patent/HUE033133T2/en unknown
- 2011-03-11 EP EP17153285.6A patent/EP3178472B1/en active Active
- 2011-10-03 UA UAA201211733A patent/UA111717C2/en unknown
2012
- 2012-08-02 TN TNP2012000392A patent/TN2012000392A1/en unknown
- 2012-08-07 CL CL2012002192A patent/CL2012002192A1/en unknown
- 2012-08-14 IL IL221452A patent/IL221452A/en active IP Right Grant
- 2012-08-23 GT GT201200247A patent/GT201200247A/en unknown
- 2012-09-19 CR CR20120476A patent/CR20120476A/en unknown
- 2012-10-02 EC ECSP12012208 patent/ECSP12012208A/en unknown
- 2012-10-10 CO CO12178897A patent/CO6630134A2/en unknown
2013
- 2013-07-31 US US13/956,050 patent/US9314461B2/en active Active
- 2013-08-14 US US13/966,779 patent/US8956651B2/en active Active
2015
- 2015-09-10 JP JP2015178184A patent/JP2016029054A/en active Pending
2016
- 2016-03-15 US US15/070,555 patent/US20160206612A1/en not_active Abandoned
2017
- 2017-08-07 JP JP2017152275A patent/JP6429955B2/en active Active
2018
- 2018-10-30 JP JP2018203748A patent/JP6647368B2/en active Active
- 2018-12-13 US US16/219,159 patent/US10376505B2/en active Active
- 2018-12-13 US US16/219,681 patent/US10307417B2/en active Active
- 2018-12-18 ZA ZA2018/08498A patent/ZA201808498B/en unknown
2019
- 2019-06-24 US US16/450,157 patent/US10507206B2/en active Active
- 2019-10-25 US US16/664,239 patent/US20200121673A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112012022873A2 (en)	2016-08-30
WO2011112816A1 (en)	2011-09-15
EA201270741A1 (en)	2013-02-28
NZ702826A (en)	2016-08-26
TW201141479A (en)	2011-12-01
EP2371357A1 (en)	2011-10-05
US20140249171A1 (en)	2014-09-04
JP2017206553A (en)	2017-11-24
CO6630134A2 (en)	2013-03-01
NZ703564A (en)	2016-08-26
BR112012022873B1 (en)	2021-09-14
PE20130063A1 (en)	2013-02-11
CR20120476A (en)	2012-11-30
US20200121673A1 (en)	2020-04-23
MX2012009125A (en)	2012-09-07
IL221452A (en)	2017-07-31
MX368805B (en)	2019-10-17
AU2011224275B2 (en)	2015-10-01
CA2789798A1 (en)	2011-09-15
KR20180118260A (en)	2018-10-30
PL3178472T3 (en)	2022-02-14
US10376505B2 (en)	2019-08-13
CN102918039A (en)	2013-02-06
TN2012000392A1 (en)	2014-01-30
MY160727A (en)	2017-03-15
ES2623926T3 (en)	2017-07-12
US10507206B2 (en)	2019-12-17
CN102918039B (en)	2017-06-09
US20190117645A1 (en)	2019-04-25
US20130330407A1 (en)	2013-12-12
US10307417B2 (en)	2019-06-04
TW201622724A (en)	2016-07-01
HK1245673A1 (en)	2018-08-31
AU2011224275A1 (en)	2012-08-23
NZ601595A (en)	2015-01-30
KR101913102B1 (en)	2018-10-31
MX349145B (en)	2017-07-14
US20160206612A1 (en)	2016-07-21
KR101982482B1 (en)	2019-05-27
US8956651B2 (en)	2015-02-17
AR080491A1 (en)	2012-04-11
US20190314365A1 (en)	2019-10-17
CN107308125B (en)	2021-07-16
MA34146B1 (en)	2013-04-03
UA123856C2 (en)	2021-06-16
EP3178472B1 (en)	2021-10-27
IL221452A0 (en)	2012-10-31
SG10201501821RA (en)	2015-05-28
JP2011190259A (en)	2011-09-29
JP2016029054A (en)	2016-03-03
GT201200247A (en)	2013-09-11
JP2019034958A (en)	2019-03-07
PH12012501622A1 (en)	2012-11-05
UA111717C2 (en)	2016-06-10
ECSP12012208A (en)	2015-03-31
CL2012002192A1 (en)	2012-09-28
SG183133A1 (en)	2012-09-27
CN107308125A (en)	2017-11-03
US9314461B2 (en)	2016-04-19
TWI605814B (en)	2017-11-21
HUE033133T2 (en)	2017-11-28
EP2371357B1 (en)	2017-02-01
CA2789798C (en)	2020-09-22
US20120070495A1 (en)	2012-03-22
JP6429955B2 (en)	2018-11-28
PL2371357T3 (en)	2017-09-29
US8524276B2 (en)	2013-09-03
JP6647368B2 (en)	2020-02-14
US20190117646A1 (en)	2019-04-25
TWI589293B (en)	2017-07-01
ZA201808498B (en)	2019-08-28
GEP201606550B (en)	2016-10-10
EP3178472A1 (en)	2017-06-14
JP6143409B2 (en)	2017-06-07
KR20130010900A (en)	2013-01-29
EA029096B1 (en)	2018-02-28

Publication	Publication Date	Title
ZA201808498B (en)	2019-08-28	Oral formulations and lipophilic salts of methylnaltrexone
ZA201209156B (en)	2016-08-31	Therapeutic oral composition
IL222406A0 (en)	2012-12-31	Improved liposomal formulations of lipophilic compounds
EP2395975A4 (en)	2013-05-22	An oral pharmaceutical composition of dutasteride
IL222919A0 (en)	2012-12-31	Alcohol - resistant oral pharmaceutical form
IL231222A0 (en)	2014-04-30	Formulations and dosage forms of oxidized phospholipids
ZA201205441B (en)	2016-01-27	Dental strip for administration of oral treatment
ZA201300160B (en)	2013-09-25	Formulations including amiodarone and salts thereof and methods of their manufacture and use
SMT202100026T1 (en)	2021-03-15	Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
IL223311A0 (en)	2013-02-03	Oral dosage forms of bendamustine
IL224191A (en)	2016-03-31	Formulations of 14 -epi-analogues of vitamin d and cmc
ZA201207945B (en)	2013-06-26	Salts of dexlansoprazole and their preparation
EP2734194A4 (en)	2015-04-22	Oral care formulations
ZA201300009B (en)	2013-09-25	Oral formulation of kinase inhibitors
PL2654723T3 (en)	2015-05-29	Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
EP2529755A4 (en)	2014-04-16	Pharmaceutical composition and preparation for oral administration
TWM390131U (en)	2010-10-11	Improved structure of dental scaler
GB0906003D0 (en)	2009-05-20	Oral drug formulation
GB201018760D0 (en)	2010-12-22	An oral dosage form
PL390434A1 (en)	2011-08-16	Medicinal preparation
TWM388322U (en)	2010-09-11	Improved structure of dental handpiece
GB201001335D0 (en)	2010-03-17	Drug release formulations
GB201012047D0 (en)	2010-09-01	Pharmaceutical formulations
GB201012046D0 (en)	2010-09-01	Pharmaceutical formulations